Disitertide
Based on 18 publication(s) in Google Scholar
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer.
For research use only. We do not sell to patients.
- Purity: 98.03%
- CAS No.: 272105-42-7
- Formula: C68H109N17O22S2
- Molecular Weight:1580.82
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Disitertide
More- Cell Death Differ. 2021 Jan;28(1):219-232. [Abstract]
- J Exp Clin Cancer Res. 2021 Feb 9;40(1):62. [Abstract]
- Int J Surg. 2025 Jul 9. [Abstract]
- Oncogene. 2019 Jun;38(23):4637-4654. [Abstract]
- Front Immunol. 2017 Feb 3:8:91. [Abstract]
- Int J Mol Med. 2019 May;43(5):2212-2220. [Abstract]
- Biochem Pharmacol. 2026 Mar 14:249:117901. [Abstract]
- Cells. 2019 Jun 25;8(6):635. [Abstract]
- Life Sci. 2026 Mar 1:388:124173. [Abstract]
- Int Immunopharmacol. 2024 Aug 21:141:112778. [Abstract]
- Sci Rep. 2026 Feb 17;16(1):9447. [Abstract]
- Funct Integr Genomics. 2024 Jul 12;24(4):123. [Abstract]
- Cancer Manag Res. 2018 Oct 10:10:4459-4470. [Abstract]
- Dig Dis Sci. 2025 May;70(5):1799-1812. [Abstract]
- Dig Dis Sci. 2021 Jun;66(6):1916-1927. [Abstract]
- Acta Histochem. 2023 Feb;125(2):152010. [Abstract]
- J BUON. 2021 Mar-Apr;26(2):435-443. [Abstract]
- Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):9-16. [Abstract]
-
WB
Biological Activity
Disitertide (P144, 100 μg/mL) suppresses the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells[2].
Disitertide (TGF-β1 inhibitor) abrogates the MACC1- AS1 expression in GC cells, suggesting that targeting TGFβ signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance[3].
Disitertide (10 μg/mL to 200 μg/mL) affects proliferation, induces apoptosis as well as anoikis in A172 and U-87 MG GBM cell lines[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse embryo osteoblast precursor MC3T3-E1 cells
-
Concentration:100 μg/mL
-
Incubation Time:4 h
-
Result:Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human hypertrophic scars were implanted in 60 nude mice[4].
-
Dosage:300 μg/mL was added the Lipogel.
-
Administration:Topical application daily administered.
-
Result:Successful shedding was achieved in 83,3% of the xenografts.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 272105-42-7
-
Appearance Solid
-
Molecular Weight 1580.82
-
Formula C68H109N17O22S2
-
Color White to off-white
-
Synonyms
P144
-
Sequence Shortening
TSLDASIIWAMMQN
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Differ
LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-β/SMAD2/3 signaling pathway. [Abstract]2021 Jan;28(1):219-232. PMID: 32737443
Disitertide purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2021 Jan;28(1):219-232. [Abstract]
LINC00941-overexpressing cells treated with Disitertide (10 μM) shows increased mRNA and protein levels of ZO-1 and Ecadherin compared with controls. LINC00941-silenced cells show decreased mRNA and protein levels of ZO-1 and E-cadherin but increased mRNA and protein levels of Vimentin, Fibronectin, and Twist1.
-
J Exp Clin Cancer Res
HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis. [Abstract]2021 Feb 9;40(1):62. PMID: 33563300 -
Int J Surg
Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer. [Abstract]2025 Jul 9. PMID: 40638251 -
Oncogene
MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. [Abstract]2019 Jun;38(23):4637-4654. PMID: 30742067 -
Front Immunol
Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts. [Abstract]2017 Feb 3:8:91. PMID: 28217129 -
Int J Mol Med
Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. [Abstract]2019 May;43(5):2212-2220. PMID: 30864698 -
Biochem Pharmacol
Endothelial Foxp1 overexpression inhibits endothelial-to-mesenchymal transition via suppressing Notch pathway activation to attenuate valvular calcification in chronic kidney disease. [Abstract]2026 Mar 14:249:117901. PMID: 41839241 -
Cells
Activation of Slit2/Robo1 Signaling Promotes Tumor Metastasis in Colorectal Carcinoma through Activation of the TGF-β/Smads Pathway. [Abstract]2019 Jun 25;8(6):635. PMID: 31242633 -
Life Sci
Galectin-9 in human trophoblast cells: Implications for maternal-fetal immune balance and pregnancy complications. [Abstract]2026 Mar 1:388:124173. PMID: 41544754 -
Int Immunopharmacol
Renal denervation improves mitochondrial oxidative stress and cardiac hypertrophy through inactivating SP1/BACH1-PACS2 signaling. [Abstract]2024 Aug 21:141:112778. PMID: 39173402 -
Sci Rep
Bmscs loaded exosome hydrogel promotes the repair of rotator cuff injury in rats in vivo. [Abstract]2026 Feb 17;16(1):9447. PMID: 41703226 -
Funct Integr Genomics
TGF-β1-Induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p/TGFBR2-SAMD2-SMAD3 Axis. [Abstract]2024 Jul 12;24(4):123. PMID: 38992207 -
Cancer Manag Res
SALL4 activates TGF-β/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis. [Abstract]2018 Oct 10:10:4459-4470. PMID: 30349378 -
Dig Dis Sci
NFAT2 Induces Tumor Cell Proliferation and Metastasis by Acting as a Transcriptional Co-activator of the TGF-β1/SMAD Signaling Pathway and Inducing the Epithelial-Mesenchymal Transition in Liver Cancer. [Abstract]2025 May;70(5):1799-1812. PMID: 40038210 -
Dig Dis Sci
Mesenchymal Stem Cell-Derived Exosomal microRNA-3940-5p Inhibits Colorectal Cancer Metastasis by Targeting Integrin α6. [Abstract]2021 Jun;66(6):1916-1927. PMID: 32671583 -
Acta Histochem
Low dose TGF-β1 can improve vohwinkel syndrome by promoting the proliferation of keratinocytes. [Abstract]2023 Feb;125(2):152010. PMID: 36738515 -
J BUON
Activation of human hepatic stellate cells enhances the metastatic ability of hepatocellular carcinoma cells via up-regulation of interleukin-1β. [Abstract]2021 Mar-Apr;26(2):435-443. PMID: 34076990 -
Eur Rev Med Pharmacol Sci
Role of miR-21 in rats with proliferative diabetic retinopathy via TGF-β signaling pathway. [Abstract]2019 Aug;23(3 Suppl):9-16. PMID: 31389569
Solvent & Solubility
H2O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
| Negative (<0) |
1. Try to dissolve the peptide in water first. 2. If water fails, add NH4OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. [Content Brief]
[2]. Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220. [Content Brief]
[3]. Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654. [Content Brief]
[4]. Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489. [Content Brief]
[5]. Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)